Docoh
Loading...

SUPN Supernus Pharmaceuticals

News

From Benzinga Pro
Supernus Pharma Reports Resubmission Of New Drug Application For SPN-830 Apomorphine Infusion Device
8 Dec 21
Biotech, News, FDA, General
ernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK
Supernus Pharmaceuticals: Q3 Earnings Insights
3 Nov 21
Earnings
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Supernus Pharmaceuticals Q3 EPS $0.40 Beats $0.23 Estimate
3 Nov 21
Earnings, News
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.23 by 73.91 percent. This is a 45.95 percent decrease over earnings of $0.74 per share
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
3 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 3, 2021
3 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

Press releases

From Benzinga Pro
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
24 Jan 22
News, Press Releases
“Biotech Stocks” It seems that the Biotech sector is now well into oversold territory and could very well see relative solid performance in 2022. Biotech stocks have been hammered back to back for two
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
8 Dec 21
Health Care, Press Releases, General
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Supernus Pharmaceuticals Targeted in Ransomware Incident
24 Nov 21
Press Releases
The attack had no significant impact on the business and did not cause any significant disruption to Company's operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24, 2021 (GLOBE
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
24 Nov 21
M&A, News, Health Care, Press Releases
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc.
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
23 Nov 21
M&A, News, Press Releases
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act)
Supernus Announces Third Quarter 2021 Financial Results
3 Nov 21
Earnings, Press Releases
Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter 2021 total revenues were $148.5 million, a 4% decrease
ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS
2 Nov 21
Press Releases
NEW ORLEANS, Nov. 2, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adamas